跳至主要内容
临床试验/NCT05486767
NCT05486767Unknown不适用

Screening of Liver Fibrosis in Adults Without Known Liver Disease or With Previously Diagnosed Non-alcoholic Fatty Liver Disease

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica3 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年8月28日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,000
试验地点
3
主要终点
Liver fibrosis

研究概览

简要总结

SIRIUS is the "serious" response to the prevalence of liver cirrhosis in Slovakia. We plan to screen adult Slovaks without acute or life-threatening comorbidity and without known liver disease (except from non-alcoholic fatty liver disease) for liver fibrosis by transient elastography (in community) or FIB-4 score (in outpatient clinics).

详细描述

According to the Lancet Gastroenterology and Hepatology, Slovakia ranks at the top of the prevalence of liver cirrhosis in the world. Moreover, liver diseases are the leading cause of death in the age-group of 25 - 50 years-old. SIRIUS is the response conceived by the governing board of the Slovak society of hepatology with two main aims: to screen for liver fibrosis and to spread the largely unknown information in community, and primary-care sector.

研究设计

研究类型
Observational
观察模型
Ecologic Or Community
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •adult, written informed consent

排除标准

  • •unable to provide sufficient reliable information for any reason
  • •withdrawal of the consent, anytime
  • •acute illness (e.g. febrile, drunk, on antibiotics, trauma, myocardial infarction < 2 months, operated on < 2 months, other)
  • •chronic disease interfering with the endpoint (malignancy < 2 years; decompensated chronic disease such as chronic heart disease with dyspnea New York heart Association NYHA 2+, Chronic obstructive pulmonary disease COPD GOLD B+, other)
  • •chronic liver disease other than non-alcoholic fatty liver disease without previous diagnosis of fibrosis

结局指标

主要结局

Liver fibrosis

时间窗: August, 2022 - to September 2023

The amount of fibrous tissue in the liver according to non-invasive tests

次要结局

  • Non-alcoholic fatty liver disease(August, 2022 - September, 2023)
  • Alcohol associated liver disease(August, 2022 - September, 2023)
  • Body mass index(August, 2022 - September, 2023)

研究者

发起方
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ľubomír Skladaný MD, PhD

MD, PhD

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

研究点 (3)

Loading locations...

相似试验

Screening of Liver Fibrosis in Adults Without Known... | 临床试验